<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939691</url>
  </required_header>
  <id_info>
    <org_study_id>18-24978</org_study_id>
    <nct_id>NCT01939691</nct_id>
  </id_info>
  <brief_title>Macular Edema Nepafenac vs. Difluprednate Uveitis Trial</brief_title>
  <acronym>MEND</acronym>
  <official_title>Macular Edema Nepafenac vs. Difluprednate Uveitis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aravind Eye Hospitals, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macular edema is a condition in which there is swelling in the macula, the part of the retina&#xD;
      that gives you your best vision. This swelling can cause your vision to decline. When&#xD;
      diagnosed early and treated, you vision usually can be preserved. However, if the swelling&#xD;
      goes untreated for a long time, it can cause permanent vision loss.&#xD;
&#xD;
      We think that the three eye drop regimens in this study, difluprednate, difluprednate plus&#xD;
      nepafenac, and prednisolone acetate plus nepafenac, might be effective in treating uveitic&#xD;
      macular edema. Patients who enter this study are randomized to one of the three regimens and&#xD;
      followed for 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial: Randomized 3 arm (1:1:1) parallel design comparative effectiveness trial&#xD;
&#xD;
      Stratification: Systemic corticosteroid/immunosuppressive therapy vs. none&#xD;
&#xD;
      Treatments: 1) difluprednate 0.05% 2) combination therapy of prednisolone acetate 1% with&#xD;
      nepafenac 0.1% 3) combination therapy of difluprednate 0.05% with nepafenac 0.1%&#xD;
&#xD;
      Masking: Unmasked treatment administration; masked outcome assessment (evaluation of OCT and&#xD;
      visual acuity)&#xD;
&#xD;
      Follow-up: 2, 4, 6, 8, and 24 weeks&#xD;
&#xD;
      Treatment protocol:&#xD;
&#xD;
      Patients will be randomized at enrollment to either:&#xD;
&#xD;
        -  difluprednate 0.05% 4 drops per day&#xD;
&#xD;
        -  prednisolone acetate 1% 4 drops per day and nepafenac 0.1% 3 drops per day&#xD;
&#xD;
        -  difluprednate 0.05% 4 drops per day and nepafenac 0.1% 3 drops per day&#xD;
&#xD;
      If macular edema has not resolved at Week 4, continue study treatment at the same dose until&#xD;
      Week 6.&#xD;
&#xD;
      If macular edema has resolved at Week 4, reduce study treatment as follows:&#xD;
&#xD;
        -  difluprednate 0.05% 1 drop per day until Week 6, then stop&#xD;
&#xD;
        -  prednisolone acetate 1% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 6,&#xD;
           then stop&#xD;
&#xD;
        -  difluprednate 0.05% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 6, then&#xD;
           stop&#xD;
&#xD;
      If macular edema does not resolve at Week 4 but has resolved at Week 6, reduce study&#xD;
      treatment at Week 6 as follows:&#xD;
&#xD;
        -  difluprednate 0.05% 1 drop per day until Week 8, then stop&#xD;
&#xD;
        -  prednisolone acetate 1% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 8,&#xD;
           then stop&#xD;
&#xD;
        -  difluprednate 0.05% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 8, then&#xD;
           stop If macular edema resolves at Week 4 but reoccurs at Week 6, treat per best medical&#xD;
           judgement.&#xD;
&#xD;
      After Week 8, there are no restrictions on the treatments patients may receive, and&#xD;
      medications can be tapered further, discontinued, or changed at the discretion of the&#xD;
      treating physician and patient preference. If a patient with previously resolved macular&#xD;
      edema has a recurrence, the physician may treat according to best medical judgement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty enrolling&#xD;
  </why_stopped>
  <start_date type="Actual">September 12, 2018</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 3 arm (1:1:1) parallel design comparative effectiveness trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Masked outcome assessment (evaluation of OCT and visual acuity)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Central subfield thickness</measure>
    <time_frame>4 weeks</time_frame>
    <description>Central subfield thickness measured by spectral domain optical coherence tomography adjusting for baseline thickness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution</measure>
    <time_frame>4 weeks</time_frame>
    <description>proportion of patients with resolution of macular edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement</measure>
    <time_frame>4 weeks</time_frame>
    <description>proportion of patients with improvement in macular edema defined as 20% or greater reduction in central subfield thickness by OCT or resolution of edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence</measure>
    <time_frame>4 weeks</time_frame>
    <description>proportion of patients with recurrence of macular edema defined as greater than 20% increase in central subfield thickness to a value &gt;320 microns by OCT or presence of cysts in an eye that previously had resolution of macular edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure (IOP) increase</measure>
    <time_frame>4 weeks</time_frame>
    <description>number of patients with intraocular pressure increase at least 10mmHg over baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High IOP</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of patients experiencing high intraocular pressure (&gt; 24 mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>4 weeks</time_frame>
    <description>best-corrected visual acuity (ETDRS protocol)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Uveitis</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Difluprednate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nepafenac plus Prednisolone acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepafenac 0.1% 3 times a day until resolution; prednisolone acetate 1% 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at Week 4, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until Week 6, then decrease to 1 drop per day until Week 8, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Difluprednate plus Nepafenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nepafenac 0.1% 3 times a day until resolution; Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Difluprednate</intervention_name>
    <description>Difluprednate 0.05% - corticosteroid eyedrop</description>
    <arm_group_label>Difluprednate</arm_group_label>
    <arm_group_label>Difluprednate plus Nepafenac</arm_group_label>
    <other_name>Durezol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac</intervention_name>
    <description>Nepafenac 0.1% - NSAID eyedrop</description>
    <arm_group_label>Difluprednate plus Nepafenac</arm_group_label>
    <arm_group_label>Nepafenac plus Prednisolone acetate</arm_group_label>
    <other_name>Nevanac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone acetate</intervention_name>
    <description>prednisolone acetate 1% - corticosteroid eyedrop</description>
    <arm_group_label>Nepafenac plus Prednisolone acetate</arm_group_label>
    <other_name>Pred Forte, Econo Pred</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        108 patients with uveitic ME will be enrolled at Aravind Eye Hospital in Madurai, India&#xD;
        based on the following eligibility criteria:&#xD;
&#xD;
        Patient-level Inclusion criteria:&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  Diagnosis of anterior, intermediate, posterior, or panuveitis (can be infectious or&#xD;
             non-infectious)&#xD;
&#xD;
          -  Inactive or minimally active inflammation according to Standardization of Uveitis&#xD;
             Nomenclature criteria (≤ 0.5+ Anterior Chamber (AC) cells, ≤ 0.5+ vitreous haze and no&#xD;
             active retinal/choroidal lesions)&#xD;
&#xD;
          -  If on oral corticosteroids, a stable dose of &lt;10 mg prednisone/day for &gt;4 weeks&#xD;
&#xD;
          -  If on systemic corticosteroid-sparing immunomodulatory therapy, a stable dose for &gt;4&#xD;
             weeks&#xD;
&#xD;
          -  If using prednisolone acetate 1% drops, stable regimen of ≤2 drops per day for &gt;4&#xD;
             weeks&#xD;
&#xD;
          -  If infectious uveitis, inflammation must be inactive or minimally active per&#xD;
             definition above and on stable dose of treatment for ≥4 weeks with no anticipated&#xD;
             changes to treatment during the trial&#xD;
&#xD;
        Eye-level Inclusion Criteria&#xD;
&#xD;
          -  ME defined as thickening of the 1mm central subfield of the macula greater than 2&#xD;
             standard deviations above normal thickness (&gt;320 µm by Heidelberg spectral-domain OCT)&#xD;
             with or without the presence of intraretinal cysts.&#xD;
&#xD;
          -  Baseline intraocular pressure &gt;5 mmHg and &lt;21 mmHg (current use ≤3 intraocular&#xD;
             pressure-lowering medications and/or prior glaucoma surgery are acceptable)&#xD;
&#xD;
          -  Media clarity and pupillary dilation sufficient to allow OCT testing and retinal&#xD;
             photography&#xD;
&#xD;
          -  Best-corrected visual acuity of 5/200 or better&#xD;
&#xD;
        Patient-level Exclusion Criteria&#xD;
&#xD;
          -  Use of oral acetazolamide or other systemic carbonic anhydrase inhibitors at baseline&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any component of the study drugs&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding (pregnancy test should be administered prior&#xD;
             to baseline fluorescein angiogram)&#xD;
&#xD;
          -  Patients unwilling or unable to not wear contact lenses during the study period&#xD;
&#xD;
          -  History of central serous chorioretinopathy in either eye&#xD;
&#xD;
        Eye-level Exclusion Criteria&#xD;
&#xD;
          -  Intravitreal or periocular corticosteroid injection in the past 8 weeks, dexamethasone&#xD;
             implant in the past 12 months, or a fluocinolone acetonide implant in the past 3 years&#xD;
&#xD;
          -  Presence of an epiretinal membrane-noted clinically or by OCT-in the study eye,&#xD;
             thought to be significant enough to preclude improvement of ME&#xD;
&#xD;
          -  Previous pars plana vitrectomy&#xD;
&#xD;
          -  History of severe glaucoma (C/D ratio &gt; 0.9 or any notching of optic nerve to rim)&#xD;
&#xD;
          -  Prior use of difluprednate or nepafenac in the past 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nisha Acharya, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Pondicherry</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 6, 2013</study_first_submitted>
  <study_first_submitted_qc>September 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>difluprednate</keyword>
  <keyword>prednisolone acetate</keyword>
  <keyword>nepafenac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Difluprednate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

